Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
94821 trials found · Page 142 of 4742
-
Magic mushroom compound could help treat anorexia in young adults
Symptom relief Recruiting nowThe goal of this clinical trial is to learn if psilocybin, given with psychological support, is safe and helps treat anorexia nervosa in young adults. Anorexia nervosa is a serious eating disorder that currently has no approved medicine. Psilocybin is a psychedelic substance that…
Phase: PHASE2 • Sponsor: Region Skane • Aim: Symptom relief
Last updated Apr 24, 2026 16:17 UTC
-
Could an MS drug help stroke patients? new trial aims to reduce deadly brain swelling
Disease control Recruiting nowSpontaneous intracerebral haemorrhage (ICH) is a life-threatening condition, still devoided of specific treatment. Peri-haematomal oedema (PHO) develops in the ensuing days after ICH onset and worsens functional outcome. Hence, PHO is a promising therapeutic target but until now …
Phase: PHASE2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated May 11, 2026 20:51 UTC
-
Engineered immune cells target abdominal cancer in early trial
Disease control Recruiting nowTo find the highest dose of NK cells that can be given by vein and intraperitoneally (given directly into the abdominal cavity) in combination with cetuximab to patients with colorectal cancer that has spread to the peritoneum.
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New stroke drug J147 shows promise in early trial
Disease control Not yet recruitingThe goal of this clinical trial is to find out if the drug J147 improves outcomes for persons who have had an ischemic stroke. It also will learn about the safety of J147 when given by injection to stroke patients. Researchers will compare the outcomes of those who receive J147 a…
Phase: PHASE2 • Sponsor: Abrexa Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New hope for kids with rare bleeding disorder: drug trial launches
Disease control Not yet recruitingThe purpose of this study is to evaluate efficacy and of safety QL0911 in the treatment of thrombocytopenia in pediatric patients with previously treated chronic ITP.
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New drug combo targets tough lung cancer that spread to liver
Disease control Not yet recruitingThe goal of this clinical trial is to learn if the combination therapy with SKB264 and anlotinib works to treat EGFR-TKI-resistant, liver-metastatic non-squamous non-small cell lung cancer (NSCLC). It will also learn about the safety of the combination therapy with SKB264 and anl…
Phase: PHASE2 • Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated May 07, 2026 18:38 UTC
-
Brain cancer patients get extended access to promising drug combo
Disease control Recruiting nowThis clinical trial is a rollover study designed to provide continued access to NBM-BMX and temozolomide (TMZ) for eligible participants with newly diagnosed glioblastoma who have completed the designated treatment in Study NBM-BMX-003 (the parent study), and to evaluate the long…
Phase: PHASE1, PHASE2 • Sponsor: Novelwise Pharmaceutical Corporation • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Lab-Grown cartilage from your own stem cells could fix knee damage
Disease control Recruiting nowThe joint cartilage constructed by combining bone marrow mesenchymal stem cells with three-dimensional materials has achieved the goal of repairing joint cartilage.
Phase: NA • Sponsor: The First Affiliated Hospital of Xinxiang Medical College • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New drug aims to slow lung scarring in autoimmune patients
Disease control Not yet recruitingInterstitial lung disease (ILD) is a common pulmonary manifestation in chronic tissue diseases (CTD), significantly affecting patient's prognosis. The main purpose of this study is to evaluate the efficacy of telitacicept compared with placebo in slowing down the decline in lung…
Phase: PHASE3 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated May 07, 2026 18:38 UTC
-
Smart insulin pump could simplify diabetes care for millions
Disease control Not yet recruitingA multi-center, 26-week randomized controlled trial (RCT) to evaluate the safety and efficacy of the fully closed loop Omnipod M System in adults with type 2 diabetes using basal/bolus insulin therapy or basal-only insulin therapy, with the primary endpoint after 15 weeks and sec…
Phase: NA • Sponsor: Insulet Corporation • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Promising new cocktail aims to shrink lung tumors
Disease control Not yet recruitingThis is a single-arm, single-center, exploratory clinical study conducted at Shanghai Pulmonary Hospital, Tongji University. The study evaluates the effectiveness and safety of first-line treatment with benmelstobart (an immunotherapy), anlotinib (an anti-angiogenic drug), platin…
Phase: PHASE2 • Sponsor: Yayi He • Aim: Disease control
Last updated May 15, 2026 21:34 UTC
-
Triple threat: new hope for liver cancer patients who failed first treatment?
Disease control Not yet recruitingThis prospective, single-arm, multicenter Phase II clinical trial aims to evaluate the efficacy and safety of Benmelstobart plus anlotinib combined with SBRT in patients with oligometastatic hepatocellular carcinoma who have failed first-line targeted therapy. Key study questions…
Phase: PHASE2 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
New drug combo aims to shrink rectal tumors before surgery
Disease control Recruiting nowThis is a multicenter, phase III, randomized controlled trial. Eligible patients with pMMR/MSS locally advanced rectal cancer will be randomized in a 1:1 ratio to either the experimental group or the control group using stratified randomization, with mesorectal fascia (MRF) statu…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 15, 2026 21:33 UTC
-
New drug duo aims to cut relapse in tough-to-treat myeloma
Disease control Not yet recruitingTo explore the efficacy and safety of thiotepa combined with melphalan for ASCT conditioning in patients with multiple myeloma who did not acheive CR with or without extramedullary inflitration before transplantation. After screening and enrollment, the patients were randomly di…
Phase: NA • Sponsor: First Affiliated Hospital Xi'an Jiaotong University • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for severe colitis: Head-to-Head drug trial launches
Disease control Recruiting nowThis clinical trial aims to evaluate the comparative efficacy and safety of upadacitinib versus infliximab as second-line treatments for acute severe ulcerative colitis, addressing the following key questions: (1) Can upadacitinib as a second-line therapy effectively induce remis…
Phase: PHASE4 • Sponsor: Xijing Hospital of Digestive Diseases • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New CAR-Treg therapy aims to tame autoimmune attacks
Disease control Not yet recruitingThe study aims to investigate the safety, tolerability, and preliminary clinical efficacy of BEN301 Injection in patients with autoimmune diseases. In patients with autoimmune diseases, Treg cells are typically deficient or dysfunctional. CAR-Treg cell therapy represents a promis…
Phase: EARLY_PHASE1 • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
New hope for hard-to-treat nose cancer: drug combo plus radiation
Disease control Not yet recruitingThis exploratory clinical study will enroll patients with unresectable locally recurrent nasopharyngeal carcinoma to receive two cycles of becotatug vedotin plus a PD-1 monoclonal antibody, followed by sequential radiotherapy and PD-1 monoclonal antibody maintenance until disease…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 05, 2026 11:53 UTC
-
Prediabetes reversal hope: new drug combo tested in major trial
Disease control Not yet recruitingThis multicenter, randomized, double-blind, placebo-controlled trial aims to evaluate the efficacy and safety of Chiglitazar Sodium combined with lifestyle intervention for reversing prediabetes to normal glucose metabolism. Eligible participants with prediabetes will be randomiz…
Phase: NA • Sponsor: Second Xiangya Hospital of Central South University • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New inhaled drug aims to help PAH patients walk farther
Disease control Not yet recruitingThe primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP compared with placebo on exercise capacity in adults with PAH.
Phase: PHASE3 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New shot could soothe severe eczema in teens
Disease control Not yet recruitingThis is a randomized, double-blind, placebo-controlled, parallel group study to confirm the efficacy and safety of MG-K10 monotherapy in adolescents with moderate-to-severe atopic dermatitis (AD)
Phase: PHASE3 • Sponsor: Shanghai Mabgeek Biotech.Co.Ltd • Aim: Disease control
Last updated May 15, 2026 11:55 UTC